 |
answer text |
<p>NHS England is leading the negotiations with Vertex and has made a revised and
improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi
in advance of assessment by the National Institute for Health and Care Excellence
(NICE), and expanded access to Kalydeco which is already funded on the National Health
Service for certain patients.</p><p>The Government fully supports NICE and NHS England
in seeking to ensure access for patients to effective and innovative medicines at
a price that represents value to the NHS, and it is not for Ministers to intervene
in this process. The Department’s approach remains to urge Vertex to accept NHS England’s
generous offer, but we will explore other options to ensure patients can access treatments
as soon as possible.</p>
|
 |
